Skip to main content

ADVERTISEMENT

Robyn Harrell, MS

Research Reports
03/08/2016
Robert M Rifkin, MD, FACP
Esprit Ma, MPH
Robyn Harrell, MS
Lina Asmar, PhD
Yanyan Zhu, PhD, MPH
Liviu Niculescu, MD
Vijayveer Bonthapally, PhD
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
...
03/08/2016
Journal of Clinical Pathways